Value-based Modifier

The Value-based Modifier (VBM) program allows for different reimbursement rates to providers under the Medicare Physician Fee Schedule based on the quality of care furnished at his or her practice, compared to the cost of care during a given reporting period. With quality measures from the PQRS program and claims data on Medicare patients, CMS is tracking providers across the country to create national benchmarks. Depending on how your practice stacks up against the national benchmark, it could be penalized or rewarded up to 4% on their Medicare Part B reimbursements.

This program will have a far-reaching impact as we shift from fee-for-service to value-based payments for physicians.

Moreover, commercial payers are beginning to phase in the same methodology for reimbursement. To see how your practice may be affected by the Value-based Modifier based on the 2016 year of care, see the graphic below.

VBM 2018 (2016 Year of Care)

Contact Miraca Life Sciences to learn how Miraca can assist your practice.
Call 1.855.347.7284 or email EHRPath@MiracaLS.com

The entire Miraca team has been the most supportive client service team we have ever dealt with. After 18 years as a clinical supervisor with our practice, I have been most impressed with the accessibility and commitment of the entire team to facilitate any and all services available to help grow our practice with the most current tools available. From Amberlyn [Abbott], our sales rep, to Lindsay [Alexander] and Zac [Whaley], our technical support, we have never heard, ‘I don’t know’ or ‘We do not do that.’ They are the most dedicated team to find answers. If they don’t have them, they find them!!
— Brenda Esser, Clinical Supervisor
Parks Dermatology Center, Daytona Beach, Fla.


READ MORE
Learn about Miraca's unmatched quality. We provide our clients with access to the highest quality AP services.

Recent News


March 27, 2017

Simponi® is Sixth Drug in InformTx™ Therapeutic Drug Monitoring Service from Miraca Life Sciences

IRVING, Texas, March 28, 2017 — Miraca Life Sciences, the largest U.S. independent anatomic pathology laboratory, continues to expand its InformTx™ therapeutic drug monitoring (TDM) capabilities, now testing for Simponi (golimumab) as well as patient-developed antibodies to Simponi. This is the first TDM assay available in the United States for Simponi. With this addition, Miraca Life Sciences now performs TDM […]

Continue reading


November 30, 2016

Stelara® Now Available for Therapeutic Drug Monitoring from Miraca Life Sciences

IRVING, Texas, December 1, 2016 — Miraca Life Sciences, the largest U.S. independent anatomic pathology lab, has expanded its InformTx™ therapeutic drug monitoring service for drugs that treat inflammatory bowel disease (IBD) with the addition of Stelara (ustekinumab).

Miraca Life Sciences continues to perform therapeutic drug monitoring (TDM) for Remicade® (infliximab), Humira® (adalimumab), Cimzia® (Certolizumab pegol) and Entyvio® (vedolizumab). Since […]

Continue reading


August 10, 2016

Ten Research Projects from Miraca Life Sciences Accepted for ACG Conference

IRVING, Texas, August 10, 2016 — Ten research projects from the GI pathologists at Miraca Life Sciences, the nation’s largest independent anatomic pathology lab, have been accepted for presentation at the Annual Meeting of the American College of Gastroenterology (ACG), which will be held October 14–19 in Las Vegas.

Authors from Miraca Life Sciences are linked below to their profile […]

Continue reading


July 13, 2016

Miraca Life Sciences Launches Easy Way to Complete GIQuIC Pathology Section

IRVING, Texas, July 13, 2016 — Working with a leading vendor of gastroenterology software, Miraca Life Sciences, the nation’s largest independent anatomic pathology lab, now enables the pathology section of the GIQuIC form to populate automatically. Miraca Life Sciences’ structured diagnosis data and smart electronic interfaces facilitate this easier process, which improves the current approach of using free-form text for […]

Continue reading


Miraca Life Sciences Adds New Way to Complete GIQuIC Pathology Section and Automate ADR Tracking

IRVING, Texas, July 13, 2016 — Miraca Life Sciences, the nation’s largest independent anatomic pathology lab, has worked closely with Wolters Kluwer throughout its latest software release of ProVation® MD to automatically populate the pathology section of the GIQuIC form for single colonoscopies, which will save hours of time for clients. Miraca Life Sciences’ use of structured diagnostic terminology combined […]

Continue reading